Drugs / mRNA-1195
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05831111 | Apr 2023 → Oct 2026 expected | Epstein-Barr virus infection | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06735248 | Apr 2025 → Jan 2029 expected | multiple sclerosis | ModernaTX, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05831111 ↗ |
| Modality | Vaccine | “A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants” NCT05831111 ↗ |
| Route | Intramuscular | “3 IM injections of mRNA-1195” NCT05831111 ↗ |